BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

NextDocs expands customer list by more than 10%

June 4, 2013 | News | By BioSpectrum Bureau



Singapore: NextDocs, the global leader in compliance solutions for regulated industries, announced that it has expanded its client roster by more than 10 percent over the past six months, adding more than a dozen new life customers. More than 100 leading life sciences and pharmaceutical companies already rely on NextDocs solutions including Astra Zeneca, McKesson, Sandoz, Sanofiand the National Cancer Center in Japan.

The companies added to the NextDocs customer roster in include a Global 2000 specialty biopharmaceutical company with more than $4 billion in revenue; a Fortune 500 healthcare products and medical device company with more than $1 billion in revenue; a global pharmaceutical company with more than $1.56 billion in revenue; and one of the largest global clinical research organizations (CRO) with operations in more than 30 countries. Approximately one-third of the new customers added in the past six months are global companies and firms headquartered in Japan.

NextDocs is the global leader in providing Microsoft SharePoint-based compliance software solutions including regulatory document management, quality management and clinical management solutions. NextDocs solutions enable businesses in regulated industries to achieve compliance with FDA and other regulations while automating processes, improving efficiency and dramatically reducing costs. The solutions help manage the creation, approval, storage, and retrieval of critical compliance and quality related documents.

Additional companies joining the NextDocs customer roster include a global healthcare company that designs and manufactures prescription and non-prescription products in over 20 countries; a leading research firm that has conducted thousands of drug safety, discovery and analytical studies; a leading consulting firm providing IRB services; a contract manufacturer of clinical trial materials, pharmaceutical intermediates, and APIs for pharmaceutical companies; a publicly traded global drug development company; and a publicly traded emerging pharmaceutical company.